Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Other Accumulated Expenses (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Other Accumulated Expenses for 11 consecutive years, with $328315.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 63.66% to $328315.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $328315.0, a 63.66% decrease, with the full-year FY2024 number at $1.7 million, up 28.61% from a year prior.
  • Other Accumulated Expenses was $328315.0 for Q3 2025 at Marker Therapeutics, down from $656631.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q4 2024 to a low of $38000.0 in Q4 2022.
  • A 5-year average of $482743.5 and a median of $354000.0 in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 84.8% in 2022, then surged 3400.0% in 2023.
  • Marker Therapeutics' Other Accumulated Expenses stood at $250000.0 in 2021, then tumbled by 84.8% to $38000.0 in 2022, then soared by 3400.0% to $1.3 million in 2023, then rose by 28.61% to $1.7 million in 2024, then plummeted by 80.81% to $328315.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Other Accumulated Expenses are $328315.0 (Q3 2025), $656631.0 (Q2 2025), and $411327.0 (Q1 2025).